<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637764</url>
  </required_header>
  <id_info>
    <org_study_id>ACT15377</org_study_id>
    <secondary_id>2018-000390-67</secondary_id>
    <secondary_id>U1111-1202-0839</secondary_id>
    <nct_id>NCT03637764</nct_id>
  </id_info>
  <brief_title>Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  Phase1: To characterize the safety and tolerability of isatuximab in combination with&#xD;
           atezolizumab in participants with unresectable hepatocellular carcinoma (HCC),&#xD;
           platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck&#xD;
           (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC), or recurrent&#xD;
           glioblastoma multiforme (GBM), and to determine the recommended Phase 2 dose (RP2D).&#xD;
&#xD;
        -  Phase2: To assess response rate (RR) of isatuximab in combination with atezolizumab in&#xD;
           participants with HCC or SCCHN or EOC.&#xD;
&#xD;
        -  Phase2: To assess the progression free survival rate at 6 months (PFS-6) of isatuximab&#xD;
           in combination with atezolizumab, or as a single agent in participants with GBM.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the safety profile of isatuximab monotherapy (GBM only), or in combination&#xD;
           with atezolizumab in Phase 2.&#xD;
&#xD;
        -  To evaluate the immunogenicity of isatuximab and atezolizumab.&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of isatuximab single agent (GBM only)&#xD;
           and atezolizumab in combination with isatuximab.&#xD;
&#xD;
        -  To assess the overall efficacy of isatuximab in combination with atezolizumab, or single&#xD;
           agent (GBM only).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient is up to 28 months including an up to 28 days screening&#xD;
      period, an up to 24 months treatment period, and a 3 months safety follow up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 3 weeks after first study treatment administration</time_frame>
    <description>DLTs as observed during DLT-observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to 90 days after last study treatment administration (Up to approximately 27 months after first study treatment administration)</time_frame>
    <description>Number of patients with AEs based on standard and systematic assessment including changes in laboratory tests and vital signs, according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 Grade scaling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 3 weeks after first study treatment administration</time_frame>
    <description>MTD determined during Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>Up to 3 weeks after first study treatment administration</time_frame>
    <description>Dose selected for the Phase 2 portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 6 months after last patient's first treatment in a given cohort</time_frame>
    <description>In patients with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC) assessed by using RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 6 months after last patient's first treatment</time_frame>
    <description>In patients with glioblastoma multiforme (GBM) assessed by using Response Assessment for Neuro-Oncology (RANO) criteria at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: isatuximab</measure>
    <time_frame>Up to 90 days following the last administration of study treatment (Up to approximately 27 months after first study treatment administration)</time_frame>
    <description>Levels of anti-drug antibody against isatuximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: atezolizumab</measure>
    <time_frame>Up to 30 days following the last administration of study treatment (Up to approximately 25 months after first study treatment administration)</time_frame>
    <description>Levels of anti-drug antibody against atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor burden change</measure>
    <time_frame>Up to 12 months after last patient's first treatment in a given cohort</time_frame>
    <description>The best percent-change from baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions in participants with HCC, SCCHN and EOC, and in a sum of products of diameters for all target lesions in participants with GBM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 12 months after last patient's first treatment in a given cohort</time_frame>
    <description>The sum of complete responses (CR) + partial responses (PR) + stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 12 months after last patient's first treatment in a given cohort</time_frame>
    <description>The time from the date of the first response (PR or CR in radiographic objective response) that is subsequently confirmed to the date of first confirmed disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>Up to 12 months after last patient's first treatment in a given cohort</time_frame>
    <description>The time from the first study treatment administration to the date of first documentation of progressive disease (RECIST 1.1 for participants with HCC, SCCHN, EOC and RANO criteria for participants with GBM) or the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 12 months after last patient's first treatment in a given cohort</time_frame>
    <description>In GBM assessed by RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Area under the curve (AUC0-T)</measure>
    <time_frame>From pre-isatuximab-dose on Cycle 1 Day 1 to 168 hours after start of isatuximab dose on Cycle 1 Day 1 (duration of assessment: 7 days; overall cycle duration: 21 days)</time_frame>
    <description>AUC0-T is the area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (T; i.e., 7 days for isatuximab) after the first infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax</measure>
    <time_frame>From pre-isatuximab-dose on Cycle 1 Day 1 to 168 hours after start of isatuximab dose on Cycle 1 Day 1 (duration of assessment: 7 days; overall cycle duration: 21 days)</time_frame>
    <description>Cmax is maximum drug concentration observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: tmax</measure>
    <time_frame>From pre-isatuximab-dose on Cycle 1 Day 1 to 168 hours after start of isatuximab dose on Cycle 1 Day 1 (duration of assessment: 7 days; overall cycle duration: 21 days)</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Neoplasm</condition>
  <arm_group>
    <arm_group_label>Phase1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and atezolizumab combination in patients with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC), or recurrent glioblastoma multiforme (GBM):&#xD;
Isatuximab dose 1 depending on DLT observed and atezolizumab predefined dose Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2-Cohort A: HCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2-Cohort B: SCCHN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2-Cohort C: EOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2-Cohort D-1:GBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2-Cohort D-2: GBM, isatuximab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2-Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and atezolizumab combination: Isatuximab dose 3 and atezolizumab predefined dose Q3W in participants with one tumor type (HCC, SCCHN, EOC, or GBM), or isatuximab monotherapy (GBM only) dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form: solution for infusion&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Phase1</arm_group_label>
    <arm_group_label>Phase2-Cohort A: HCC</arm_group_label>
    <arm_group_label>Phase2-Cohort B: SCCHN</arm_group_label>
    <arm_group_label>Phase2-Cohort C: EOC</arm_group_label>
    <arm_group_label>Phase2-Cohort D-1:GBM</arm_group_label>
    <arm_group_label>Phase2-Cohort D-2: GBM, isatuximab monotherapy</arm_group_label>
    <arm_group_label>Phase2-Cohort E</arm_group_label>
    <other_name>Sarclisa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Pharmaceutical form: solution for infusion&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Phase1</arm_group_label>
    <arm_group_label>Phase2-Cohort A: HCC</arm_group_label>
    <arm_group_label>Phase2-Cohort B: SCCHN</arm_group_label>
    <arm_group_label>Phase2-Cohort C: EOC</arm_group_label>
    <arm_group_label>Phase2-Cohort D-1:GBM</arm_group_label>
    <arm_group_label>Phase2-Cohort E</arm_group_label>
    <other_name>Tecentriq®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Patients must have a known diagnosis of either unresectable hepatocellular carcinoma&#xD;
             (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head&#xD;
             and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC) with&#xD;
             evidence of measurable disease or recurrent glioblastoma multiforme (GBM).&#xD;
&#xD;
          -  ≥18 years of age.&#xD;
&#xD;
          -  For patients with HCC: Documentation of progressive disease (PD) during or after&#xD;
             treatment with either sorafenib or lenvatinib, or intolerance to the therapy.&#xD;
&#xD;
          -  For patients with SCCHN: Received and failed up to 2 lines of prior systemic&#xD;
             anti-cancer therapy with documentation of tumor recurrence or PD within 6 months of&#xD;
             last platinum-based therapy in primary, recurrent, or metastatic setting.&#xD;
&#xD;
          -  For patients with EOC: Received up to 3 lines of prior platinum-containing therapy&#xD;
             when the disease was platinum-sensitive, and the patients should not have received any&#xD;
             systemic therapy for platinum-resistant/refractory disease. specific to France only:&#xD;
             Documentation of PD on or after 1 line of anti-cancer therapy for platinum&#xD;
             resistant/refractory disease (unless patients are ineligible or intolerant to standard&#xD;
             of care for platinum-resistant/refractory disease).&#xD;
&#xD;
          -  For patients with GBM: Documentation of PD or first recurrence during or after&#xD;
             temozolomide maintenance therapy for newly diagnosed GBM treated with 1st line&#xD;
             radiotherapy plus concurrent temozolomide.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior exposure to agent that blocks CD38 or participation in clinical studies with&#xD;
             isatuximab.&#xD;
&#xD;
          -  For patients with HCC, SCCHN, EOC or GBM prior exposure to any agent (approved or&#xD;
             investigational) that blocks the PD-1/PD-L1 pathway.&#xD;
&#xD;
          -  Evidence of other immune related disease /conditions.&#xD;
&#xD;
          -  History of non-infectious pneumonitis requiring steroids or current pneumonitis;&#xD;
             history of the thoracic radiation.&#xD;
&#xD;
          -  Has received a live-virus vaccination within 28 days of planned treatment start.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted.&#xD;
&#xD;
          -  Prior solid organ or bone marrow transplantation.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (PS) ≥2 for patients with HCC,&#xD;
             SCCHN or EOC or Karnofsky performance score ≤ 70 for patients with GBM.&#xD;
&#xD;
          -  Poor bone marrow reserve.&#xD;
&#xD;
          -  Poor organ function.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400207</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400007</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0560001</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0560002</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240001</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030001</name>
      <address>
        <city>Brno</city>
        <zip>65653</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030003</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030002</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800007</name>
      <address>
        <city>Meldola</city>
        <state>Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800003</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800009</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800004</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :5280001</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240001</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240006</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Castilla Y León</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240003</name>
      <address>
        <city>Madrid / Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240004</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240008</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240007</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580005</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580002</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580001</name>
      <address>
        <city>Taipei 100</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580003</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580006</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580004</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Greece</country>
  </removed_countries>
  <verification_date>October 19, 2021</verification_date>
  <study_first_submitted>August 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-CD38 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

